NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...
Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...
AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha ...
The US FDA has approved Vyloy in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction cancer.
The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened ...
This study highlights the clinical utility of the PredicineCARE™ liquid biopsy assay in Roche’s pivotal INAVO120 Phase 3 clinical trial of Inavolisib (Itovebi), which targets patients with ...
This adds value to multiplex assays, proving to be a positive market force. Key Findings from the Market Report The global multiplex assay market is segmented based on product type, the technology ...
Under this agreement, the Bladder CAREâ„¢ Assay will be covered by insurance, enhancing access for patients. This strategic collaboration aims to streamline cancer diagnostics in Switzerland ...
Under the terms of the partnership, Alamar Biosciences and ADx NeuroSciences will combine their respective expertise to provide tailored assay solutions to meet the specific needs of ...
MicroRNAs (miRNAs) are valuable biomarkers for the diagnosis and prognosis of diseases. The 2024 Nobel Prize in Physiology or Medicine has been awarded to American scientists Victor Ambros and ...
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2024) - Equity Metals Corporation (TSXV: EQTY) ("Equity") reports final assay results from the Summer '24 drill program on its 100% owned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback